Pfizer Stock News

New data suggest the Pfizer-BioNTech Covid vaccine works substantially less well at preventing infection and hospitalizations in kids 5 to 11.

Total number of positive cases stand at 322,946 Kenya has received an additional 1.8 million doses of COVID-19 vaccines from COVID-19 Vaccines Global Access (COVAX), a worldwide initiative aimed at equitable access to COVID-19 vaccines. The consignment donated by the United States government will be distributed to six counties; Mombasa, Nairobi, Kakamega, Nakuru, Kisumu, Eldoret while the remainder will be stored at the central stores in Kitengela. Ministry of Health officials led by Benjamin Murkomen, the Port Health Officer in charge at Jomo Kenyatta International Airport (JKIA) were on ground to receive the consignment from Eric Watnik, the Public Diplomacy Counsellor at US embassy. Watnik pointed out the achievements Kenya has made over the last six months in the fight against the Covid-19 pandemic are significant including administering over 13.8 million doses of vaccines countrywide. Ministry of Health officials led by the Port Health Officer in charge at Jomo Kenyatta International Airport (JKIA) Benjamin Murkomen were on ground to receive the consignment from Eric Watnik the Public Diplomacy Counsellor at US embassy.

The government lauded US government for its continued support to the country.

Beam Therapeutics press release (BEAM): Q4 GAAP EPS of -$0.95.Revenue of $51.07M.Shares -5.11% PM. Strong Cash Position of $1.2 Billion, Including Pfizer Upfront, to Support Robust Set…

Research Collaboration with Pfizer Underway, with Upfront and Potential Milestone Payments of Up to $1.35 Billion

PITTSBURGH , Feb. 28, 2022 /PRNewswire/ -- Biocon Biologics Transaction Consists of Pre-tax Consideration of up to $3.335 billion , Including $2 billion in Upfront Cash, $1 billion of Convertible Preferred Equity Representing a Stake of at Least 12.9% in Biocon Biologics (on a Fully Diluted Basis), and up to $335 million of Additional Payments. Rajiv Malik , Viatris President, to Represent Viatris on Biocon Biologics Board. Transaction is Expected to Close in Second Half of 2022 Material Benefits of the Transaction Upon Closing Include: Crystalizes Value Accretion at Approximately Triple Current Standalone Multiple Nearly 2/3 in Immediate Cash Proceeds Additional Potential Upside Participation Through Equity Stake with Governance Participation Frees up R&D and Capital Spend to Redeploy in a More Concentrated Way Enhances Immediate Additional Availability of Capital to Accelerate Reinvestment into Business or Share Repurchases Accelerates Phase I Financial Commitments Reduces Complexity and Execution Risk Enhances Viatris'' Margin Profile Reshaping Plan Also Identified Other Select Assets Which the Company Expects Will Unlock Additional Value of up to Approximately $6 billion in Pre-tax Proceeds by the End of 2023 Company Announces First Global Healthcare Gateway® Transaction Focused on Ophthalmology Company Provides 2022 Financial Guidance Company Hosts Virtual Investor Event to Detail the Company''s Long-Term Strategic Direction (1) Refers to 2022 estimated adjusted EBITDA of Viatris'' biosimilars portfolio of approximately $200 million .

New Zealand High Court: Vaccine Mandate Not "Demonstrably Justified", Breach Of Rights Authored by Katabella Robert via The Epoch Times (emphasis ours), The New Zealand High Court has upheld a challenge to a vaccine mandate for Police and Defence Force staff, stating that it was not a “demonstrably justified” breach of the Bill of Rights. Police stop vehicles to heading north on state highway one at Warkworth in Auckland, New Zealand, on April 09, 2020. (Fiona Goodall/Getty Images) Justice Francis Cooke was asked by a group of Police and Defence Force personnel to judicially review the vaccine mandate enacted under the COVID-19 Public Health Response Act in December. The mandate required all Defence Force personnel and all Police constables, recruits, and authorized officers to receive two doses of the vaccine by March 1. But on Jan. 6, three unvaccinated staff who did not wish to receive the shots sought a judicial review of the mandate. They were supported by affidavits from 37 of their colleagues in the same position.

For about two years, we’ve been told unequivocally that the mRNA vaccine will not integrate itself permanently into our DNA. Now a new study of Sweden just confirms one of our worst fears. It turns out that the RNA from the Pfizer […] The post New Swedish study shows that Pfizer vaccine becomes DNA in liver cells in as fast as 6 hours, in-vitro appeared first on Tech News | Startups News .

Making sure adults and older children are vaccinated is the best thing to do if worried about under-fives not being eligible, expert says Follow our Australia news live blog for the latest updates Get our free news app ; get our morning email briefing Children under the age of five are not yet able to be vaccinated against Covid leaving some parents worried their younger children could catch the virus from older siblings who have returned to school. Less than 50% of children aged five to 11 have received their first vaccine dose. But it is hoped child vaccination rates will be bolstered by Australia becoming the first country to approve the Moderna vaccine for children aged six and over. Pfizer continues to be available to children aged five and over. Continue reading…

TOKYO—Drugmaker Shionogi & Co. Ltd. has applied for approval to make and sell its oral COVID-19 treatment in Japan, the firm said on Friday. Known as S-217622, the drug would become the country’s third antiviral pill approved for coronavirus patients, following those developed by Pfizer Inc. and Merck & Co.. In a statement, Shionogi said […]

A protein-based vaccine that GlaxoSmithKline and Sanofi hope to get approved has several advantages over mRNA-based vaccines made by companies like Moderna and Pfizer.

Growing Number Of Experts Call On US Govt To Recognize Natural Immunity Authored by Zachary Stieber via The Epoch Times, A growing number of experts are urging the U.S. government to formally recognize natural immunity , or the protection given by recovering from COVID-19 . More experts are arguing that the Centers for Disease Control and Prevention’s (CDC) recommended vaccination schedule should feature fewer doses—or none at all—for people who have contracted COVID-19 and survived. “Natural infection should count as two doses,” Dr. Paul Offit, professor of pediatrics at the Children’s Hospital of Philadelphia, and an adviser to the Food and Drug Administration on vaccines, told The Epoch Times. Offit and two former FDA officials stated in a recent op-ed that “requiring people who have been infected to get three shots is overkill at best—a waste of valuable doses—and an unnecessary risk at worst (given that vaccines have side effects, albeit rare ones).” Under current CDC guidance, all Americans 12 and older are advised to get three doses of the Moderna or Pfizer COVID-19 vaccines.

Watch Video European drugmakers Sanofi and Glaxosmithkline (GSK) released data showing their COVID vaccine is 100% effective at keeping patients out of the hospital. It has not been independently scientifically reviewed. Drugmakers Sanofi and GlaxoSmithKline have asked the Food and Drug Administration for emergency use authorization of their vaccine. "We are confident that this vaccine can play an important role as we continue to address this pandemic and prepare for the post-pandemic period," Roger Connor, president of GSK, said in a statement. Sanofi''s and GSK''s vaccine is based on a more conventional protein-based vaccine technology. It''s a recombinant protein vaccine, which means it recombines different segments of DNA. This uses DNA from the SARS-COV-2 spike protein, which COVID needs to enter and infect healthy cells. The combined DNA helps fire up your immune response. This is different from Pfizer and Moderna''s mRNA, or messenger RNA, technology. That vaccine uses a genetic code to teach the body''s cells how to make proteins that trigger immune responses.

Pfizer (PFE) announced on Friday that the U.S. Food and Drug Administration ((FDA)) accepted its supplemental marketing application for Abrilada (adalimumab-afzb) that sought…

Companies including Pfizer and Moderna so far have reported at least $79 billion in combined global sales of Covid-19 vaccines and treatments for 2021.